Pronostics Ltd.
This article was originally published in Start Up
Executive Summary
Pronostics is developing molecular fingerprint profiling technology that it describes as a "digital multiplex solution. Its UltraPlex platform uses microscopic aluminum microparticles, each with a unique physical barcode etched onto the surface. Applications for UltraPlex multiplexed assays include direct immunoassays, sandwich ELISAs, DNA hybridization, activity assays, receptor binding assays, and cell-based assays. The first focus for the technology is autoimmune disease, and three UltraPlex multiplexed assays, ANA, thyroid, and celiac disease, are available.
You may also be interested in...
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Start-Ups Against Inflammation," features profiles of Asphleia Pharmaceuticals, Calistoga Pharmaceuticals, ProtAb Ltd., and Resolvyx Pharmaceuticals. Plus these Start-Ups Across Health Care: CG Therapeutics, Healionics, Mpathy Medical Devices and Pronostics.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.